Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

605

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

March 25, 2020

Study Completion Date

April 28, 2023

Conditions
Mesothelioma
Interventions
BIOLOGICAL

Nivolumab

BIOLOGICAL

Ipilimumab

DRUG

Pemetrexed

DRUG

Cisplatin

DRUG

Carboplatin

Trial Locations (109)

0

Local Institution - 0124, Kunming

Local Institution - 0039, Bogotá

Local Institution - 0040, Bogotá

1011

Local Institution - 0036, Lausanne

1090

Local Institution - 0089, Brussels

2139

Local Institution - 0032, Sydney

2650

Local Institution - 0086, Edegem

3010

Local Institution - 0049, Bern

3144

Local Institution - 0030, Malvern

3168

Local Institution - 0033, Clayton

4000

Local Institution - 0087, Liège

4575

Local Institution - 0031, Birtinya

6009

Local Institution - 0034, Nedlands

7570

Local Institution - 0059, Cape Town

8091

Local Institution - 0029, Zurich

9100

Local Institution - 0088, Sint-Niklaas

10065

Memorial Sloan Kettering Nassau, New York

11527

Local Institution - 0017, Athens

13915

Local Institution - 0069, Marseille

14000

Local Institution - 0053, Mexico City

14033

Local Institution - 0057, Caen

14050

Local Institution - 0050, Mexico City

15212

Allegheny Cancer Center, Pittsburgh

16132

Local Institution - 0045, Genova

19104

University Of Pennsylvania, Philadelphia

20089

Local Institution - 0048, Rozzano

21075

Local Institution - 0027, Hamburg

21201

Univ Of Maryland Greenbaum Cancer Center, Baltimore

21280

Local Institution - 0111, Diyarbakır

22927

Local Institution - 0024, Großhansdorf

26506

West Virginia University, Morgantown

31000

Local Institution - 0118, Chihuahua City

31059

Local Institution - 0068, Toulouse

33081

Local Institution - 0047, Aviano

33612

H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa

34098

Local Institution - 0112, Istanbul

34376

Local Institution - 0022, Immenhausen

37075

Local Institution - 0023, Göttingen

38700

Local Institution - 0074, La Tronche

44195

Local Institution - 0007, Cleveland

44270

Local Institution - 0051, Guadalajara

44805

Local Institution - 0080, Saint-Herblain

45147

Local Institution - 0038, Essen

47441

Local Institution - 0019, Moers

48121

Local Institution - 0042, Ravenna

48201

Local Institution - 0013, Detroit

49503

Cancer & Hematology Centers Of Western Michigan, Grand Rapids

51109

Local Institution - 0026, Cologne

53100

Local Institution - 0041, Siena

55905

Local Institution - 0004, Rochester

57001

Local Institution - 0016, Thessaloniki

59037

Local Institution - 0067, Lille

60637

Local Institution - 0002, Chicago

66421

Local Institution - 0021, Homburg An D. Saar

67091

Local Institution - 0093, Strasbourg

69126

Local Institution - 0037, Heidelberg

70124

Local Institution - 0044, Bari

75018

Local Institution - 0056, Paris

77030

Local Institution - 0005, Houston

80131

Local Institution - 0043, Napoli

83056

Local Institution - 0058, Toulon

94010

Local Institution - 0073, Créteil

94143

Ucsf, San Francisco

95124

Local Institution - 0046, Catania

115478

Local Institution - 0150, Moscow

121309

Local Institution - 0071, Moscow

130021

Local Institution, Changchun

150081

Local Institution - 0133, Harbin

197758

Local Institution - 0072, Saint Petersburg

200030

Local Institution - 0120, Shanghai

200347

Local Institution - 0102, Craiova

400015

Local Institution - 0055, Romania

1040045

Local Institution - 0094, Chuo-ku

2210855

Local Institution - 0095, Yokohama

2608677

Local Institution - 0097, Chiba

3620806

Local Institution - 0096, Kitaadachi-gun

4668560

Local Institution - 0105, Nagoya

5898511

Local Institution - 0113, Sayama

6608550

Local Institution - 0106, Amagasaki-shi

6638501

Local Institution - 0098, Nishinomiya-shi

7028055

Local Institution - 0100, Okayama

7200001

Local Institution - 0108, Fukuyama-shi

7348551

Local Institution - 0114, Hiroshima

7550241

Local Institution - 0099, Ube-shi

8420383

Local Institution - 0018, Santiago

9518520

Local Institution - 0107, Niigata

9811293

Local Institution - 0104, Natori-shi

06520

Local Institution - 0014, New Haven

14784-400

Local Institution, Barretos

05403-010

Local Institution - 0064, São Paulo

Unknown

Local Institution, Shenyang

01640

Local Institution - 0054, Coswig

0030804

Local Institution - 0101, Sapporo

06720

Local Institution - 0079, Df

1066 CX

Local Institution - 0092, Amsterdam

3000 CA

Local Institution - 0091, Rotterdam

41-902

Local Institution - 0078, Bytom

31-202

Local Institution - 0076, Krakow

02-781

Local Institution - 0077, Warsaw

020122

Local Institution - 0115, Bucharest

021389

Local Institution - 0109, Bucharest

0075

Local Institution - 0060, Pretoria

01130

Local Institution - 0110, Seyhan

TR1 3LJ

Local Institution - 0085, Truro

EH4 2XU

Local Institution - 0084, Edinburgh

LE1 5WW

Local Institution - 0081, Leicester

EC1A 7BE

Local Institution - 0083, London

M23 9LT

Local Institution - 0116, Manchester

SO16 6YD

Local Institution - 0090, Southampton

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT02899299 - Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | Biotech Hunter | Biotech Hunter